drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Adoptive γδ T‑cell therapy using Vγ9Vδ2 T cells expanded from healthy donors and administered intraventricularly/intracavitary via an Ommaya reservoir. These innate‑like cytotoxic lymphocytes recognize tumor phosphoantigens via BTN3A1/BTN2A1 independent of MHC, triggering perforin/granzyme‑mediated killing and cytokine release; they can also respond via NKG2D and mediate ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Gamma-Delta
drug_category
CULTURED CELLS
drug_class
Unedited cells
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Allogeneic Vγ9Vδ2 T cells recognize tumor-derived phosphoantigens generated by dysregulated mevalonate metabolism via BTN3A1/BTN2A1 in an MHC-independent manner, triggering perforin/granzyme-mediated cytotoxicity and cytokine release. They also respond to stress ligands through NKG2D and can mediate ADCC.
drug_name
Allogeneic Vγ9Vδ2 T cells
nct_id_drug_ref
NCT06396481